DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
OpenAI Restricts Astra AI Over Cyberattack Risks 
SAN FRANCISCO, March 07, 2018 -- Hagens Berman Sobol Shapiro LLP alerts Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) investors to the expanded class period and the April 10, 2018 Lead Plaintiff deadline in the pending securities class action. If you purchased or otherwise acquired Synergy securities between November 10, 2016 and November 14, 2017 and suffered losses, contact Hagens Berman Sobol Shapiro LLP. For more information, visit:
https://www.hbsslaw.com/cases/SGYP
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing
The complaint charges defendants with falsely describing the terms of a $300 million senior secured loan to Synergy as non-dilutive to shareholders.
However, when Synergy disclosed the loan agreement in an SEC filing on November 9, 2017, its terms revealed that the loan would likely be dilutive. This news drove the price of Synergy shares down $0.25, or about 8.4%, to close at $2.72 on November 10, 2017.
Then, on November 14, 2017, Synergy filed a prospectus for the issuance of nearly 22 million shares and warrants to purchase nearly 22 million shares. This news drove the price of Synergy shares down $0.14, or about 6.9% to close at $1.89 on November 15, 2017.
“We’re focused on the defendants’ statements about the financing’s impact on investors that, if false, damaged them,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Synergy Pharmaceuticals should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 70+ attorneys in 11 offices across the country. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000
